{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:07:49Z","timestamp":1788847669093,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cachexia is a devastating metabolic syndrome that has a profound impact on survival rate and quality of life. Currently, there is still a scarcity of systematic evidence regarding drug-induced cachexia. This study aims to identify drugs associated with cachexia through the first large-scale pharmacovigilance analysis, and to characterize their risk features using real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the U.S. FDA Adverse Event Reporting System (FAERS) from January 2004 and March 2025 were analyzed. Reports listing cachexia as an adverse event were extracted. Disproportionality analysis was performed on the top 50 most frequently reported drugs using reporting odds ratio (ROR), proportional reporting ratio, Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker. A drug was considered a positive signal only if it met the threshold across all four methods. The Weibull shape parameter test was used to analyze the time-to-onset (TTO) profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 4,878 individual case safety reports of drug-related cachexia, the mortality rate was 25.6%. Disproportionality analysis identified 25 drugs with consistent positive signals across all four algorithms. These drugs spanned nine categories, with antineoplastic and immunomodulating agents being the most common. The drugs with stronger signals were low calcium peritoneal dialysis solution lactate G15 (ROR 495.67, 95% CI 336.94\u2013729.18), Kaletra (ROR 10.44, 95% CI 7.98\u201313.65), and nivolumab (ROR 15.29, 95% CI 13.65\u201317.13). The drugs with a higher number of reported cases were nivolumab (319 cases), paclitaxel (160 cases), and Zometa (131 cases). The median TTO was 31\u00a0days, and more than half of cases occurred within the first 120\u00a0days, presenting an \u201cearly failure\u201d pattern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified 25 drug safety warning signals that are significantly associated with the occurrence of cachexia. Cachexia is more likely to occur in the initial stage of drug treatment and has a high mortality rate. Continuous regulatory review and label updates of the safety information of relevant medications should be promoted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1913539","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:35:32Z","timestamp":1788845732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for drug-related cachexia: an analysis based on the FDA adverse event reporting system (FAERS) from 2004 to 2025"],"prefix":"10.3389","volume":"17","author":[{"given":"Lingli","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchen","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Scientific Research, Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3390\/cancers14092107","article-title":"Molecular mechanisms and current treatment options for cancer cachexia","volume":"14","author":"Ahmad","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40261-022-01141-x","article-title":"Nutrition and chronic liver disease","volume":"42","author":"Aller de la Fuente","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"B3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argiles","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/jcm10071377","article-title":"Genetics of acromegaly and gigantism","volume":"10","author":"Boguslawska","year":"2021","journal-title":"J. Clin. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11864-019-0691-9","article-title":"Chemotherapy-induced sarcopenia","volume":"21","author":"Bozzetti","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/jcsm.12232","article-title":"Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice","volume":"8","author":"Brown","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/jac\/dkv494","article-title":"Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-Infected patients","volume":"71","author":"Calza","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.jrn.2013.01.001","article-title":"Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM)","volume":"23","author":"Carrero","year":"2013","journal-title":"J. Ren. Nutr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"18063","DOI":"10.1038\/s41598-025-01206-9","article-title":"Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.jrn.2008.02.001","article-title":"Adipocytokines leptin and adiponectin, and measures of malnutrition-inflammation in chronic renal failure: is there a relationship?","volume":"18","author":"Dervisoglu","year":"2008","journal-title":"J. Ren. Nutr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"101598","DOI":"10.1016\/j.beem.2021.101598","article-title":"Therapeutic effects of androgens for cachexia","volume":"36","author":"Giovanelli","year":"2022","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/nejmoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/jcpe.70040","article-title":"Pharmacovigilance-based identification and mechanistic exploration of periodontitis-related drugs","volume":"53","author":"Huoshen","year":"2026","journal-title":"J. Clin. Periodontol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1139\/cjpp-2024-0128","article-title":"Cardiovascular adverse events associated with norepinephrine-dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System","volume":"102","author":"Kandukuru","year":"2024","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.jana.2012.06.013","article-title":"HIV-associated wasting","volume":"24","author":"Keithley","year":"2013","journal-title":"J. Assoc. Nurses AIDS Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"110913","DOI":"10.1016\/j.isci.2024.110913","article-title":"Sorafenib induces cachexia by impeding transcriptional signaling of the SET1\/MLL complex on muscle-specific genes","volume":"27","author":"Khan","year":"2024","journal-title":"iScience"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1158\/2159-8290.CD-25-0293","article-title":"Cancer-associated cachexia: bridging clinical findings with mechanistic insights in human studies","volume":"15","author":"Koh","year":"2025","journal-title":"Cancer Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cmet.2024.10.017","article-title":"Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1","volume":"37","author":"Lin","year":"2025","journal-title":"Cell Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A review of the toxicity of HIV medications","volume":"10","author":"Margolis","year":"2014","journal-title":"J. Med. Toxicol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10198-017-0930-6","article-title":"Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia","volume":"20","author":"Meregaglia","year":"2019","journal-title":"Eur. J. Health Econ."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e47258","DOI":"10.15252\/embr.201847258","article-title":"Energy metabolism in cachexia","volume":"20","author":"Rohm","year":"2019","journal-title":"EMBO Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.11.002","article-title":"Protein breakdown in cancer cachexia","volume":"54","author":"Sandri","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.jrn.2020.08.003","article-title":"Which method should be used to assess protein intake in peritoneal dialysis patients? Assessment of agreement between protein equivalent of total nitrogen appearance and 24-Hour dietary recall","volume":"31","author":"Silva","year":"2021","journal-title":"J. Ren. Nutr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/1346-8138.17517","article-title":"Immune checkpoint inhibitor-associated bullous pemphigoid: a retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system","volume":"52","author":"Tan","year":"2025","journal-title":"J. Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.critrevonc.2015.12.008","article-title":"Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: a systematic review","volume":"99","author":"Tarricone","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13539-014-0164-8","article-title":"Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014","volume":"5","author":"von Haehling","year":"2014","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"B32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pharmthera.2008.09.009","article-title":"Cardiac cachexia: a systematic overview","volume":"121","author":"von Haehling","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"40477","DOI":"10.1074\/jbc.M111.257923","article-title":"Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-alpha (TNF-alpha)-induced lipolysis in adipocytes","volume":"286","author":"Yang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"105833","DOI":"10.1016\/j.archger.2025.105833","article-title":"Prevalence and prognostic significance of cachexia diagnosed by novel definition for Asian population among Chinese cirrhotic patients","volume":"133","author":"Yao","year":"2025","journal-title":"Arch. Gerontol. Geriatr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s12276-022-00752-w","article-title":"Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia","volume":"54","author":"Yeom","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1438661","DOI":"10.3389\/fphar.2024.1438661","article-title":"A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"103957","DOI":"10.1016\/j.identj.2025.103957","article-title":"Identification of drugs associated with oral ulcers based on pharmacovigilance","volume":"75","author":"Zhang","year":"2025","journal-title":"Int. Dent. J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"112697","DOI":"10.1016\/j.nut.2025.112697","article-title":"Research progress on the mechanism and treatment of cachexia based on tumor microenvironment","volume":"133","author":"Zhao","year":"2025","journal-title":"Nutrition"},{"key":"B39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0962280211403602","article-title":"Disproportionality methods for pharmacovigilance in longitudinal observational databases","volume":"22","author":"Zorych","year":"2013","journal-title":"Stat. Methods Med. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1913539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:35:32Z","timestamp":1788845732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1913539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":39,"alternative-id":["10.3389\/fphar.2026.1913539"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1913539","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1913539"}}